Definium Therapeutics Announces Positive Phase 3 Panorama Study Results for DT120 ODT in Generalized Anxiety Disorder
DFTX has more than doubled off its 52-week low of $8.773.
Summary
Definium Therapeutics announced positive topline results from its Phase 3 Panorama study of DT120 ODT for generalized anxiety disorder, marking the third successful Phase 3 trial for the drug and paving the way for an NDA filing in 1H 2027.
Key Events · Product Development and Regulatory · DFTX
-
Positive Phase 3 Results for DT120 ODT in GAD
The Panorama study met its primary and all key secondary efficacy endpoints, showing a statistically significant and clinically meaningful reduction in Hamilton Anxiety Rating Scale (HAM-A) scores for generalized anxiety disorder (GAD). The DT120 ODT 100 µg arm achieved a placebo-adjusted change of -5.1 points from baseline at Week 12 (p<0.0001).
-
Consistent Efficacy and Safety Profile
DT120 ODT 100 µg demonstrated rapid, robust, and durable efficacy, with changes seen as early as Day 2 and sustained. The drug was generally well tolerated, with a safety profile consistent with prior clinical experience and no new safety signals, including no suicidality signal.
-
Third Positive Phase 3 Readout for Lead Candidate
This marks the third successful Phase 3 trial for DT120 ODT, following positive Emerge results in Major Depressive Disorder (MDD) in June and positive Voyage results in GAD in August. This strengthens the drug's profile across multiple psychiatric disorders.
-
Advancing Towards NDA Submission
The company has scheduled a pre-NDA meeting in Q4 2026 and anticipates filing a New Drug Application (NDA) in 1H 2027, leveraging a robust data package from its successful clinical program.
Analysis · DFTX · Life Sciences
This 8-K announces another highly positive Phase 3 clinical trial result for Definium Therapeutics' lead candidate, DT120 ODT, this time for generalized anxiety disorder (GAD). The Panorama study successfully met its primary and all key secondary endpoints, demonstrating significant and rapid improvement in anxiety symptoms with a favorable safety profile. This is the third positive Phase 3 readout for DT120 ODT across two indications (GAD and MDD), building a compelling body of evidence for the drug's efficacy and safety. The company is now firmly on track for a pre-NDA meeting in Q4 2026 and an NDA filing in 1H 2027, which significantly de-risks the commercialization path for this potential best-in-class treatment.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DFTX was trading at $45.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $8.77 to $49.70. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.